Literature DB >> 9803550

[Percutaneous balloon pulmonary valvuloplasty: the medium-term results in a series of 100 consecutive pediatric patients].

M A Hernáez Cobeño1, R Bermúdez-Cañete, I Herraiz, L Fernández Pineda, C Quero Jiménez, P Díaz García.   

Abstract

OBJECTIVE: To study medium-term follow-up in children with pulmonary stenosis (PS) with percutaneous balloon pulmonary valvuloplasty (PBVP). PATIENTS AND METHODS: Medium-term follow-up results of 106 consecutive PBVP procedures in 100 patients of the same health center are presented. The mean age of the patients was 61.3 +/- 5.1 months, 31 of them with severe PS.
RESULTS: After PBVP, and once infundibular contraction ceased, the procedure was defined as successful in 85 children. PBVP was repeated in five patients, achieving satisfactory results in 3. Eight patients suffered from re-stenoses and surgery was performed in 7 of them. The other 12 patients in which PBVP failed underwent surgery. Follow-up of these 88 patients showed a cessation in clinical symptomatology at a mean of 10 +/- 0.7 months. Five-year actuarial probability of achieving a normal EKG axis was 61.7 +/- 9.1%. However, neither ECG nor chest radiology were useful in the diagnosis of high residual gradients. Pulmonary regurgitation was observed in 92% of the children, mild in all of them. The residual transpulmonary gradient obtained immediately after PBVP was the only variable that affected long-term results.
CONCLUSIONS: Our results confirm the medium-term success of PBVP in the treatment of PS. The five year actuarial probability of restenosis is 12.4%. Mild pulmonary regurgitation is observed in more than 90% of patients.

Entities:  

Mesh:

Year:  1998        PMID: 9803550

Source DB:  PubMed          Journal:  An Esp Pediatr        ISSN: 0302-4342


  1 in total

1.  Long-term Results of Balloon Pulmonary Valvuloplasty in Children with Congenital Pulmonary Valve Stenosis.

Authors:  Behjati-Ardakani Maostafa; Moshtaghion Seyed-Hossien; Rajaei Shahrokh
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.